Somatostatin
DOI:
https://doi.org/10.29303/jku.v10i2.482Keywords:
Somatostatin, Somatostatin analog, SSTR, PRRTAbstract
Somatostatin, also known as growth hormone-inhibiting factor (GIF) or somatotropin release-inhibiting factor (SRIF), is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation. Somatostatin can be regarded as secretory pan-inhibitory,because it can inhibit secretion of almost all endocrine and exocrine glands. Somatostatin has 2 active forms (somatostatin-14 and 28), but the short half-life of the hormone was one of the reasons why the native hormone was not feasible for routine clinical practice. Somatostatin analog was synthesized for the first time in 1980-1982 and proved to be more resistant to degradation and more potent than native hormone. There are five somatostatin receptors (SSTR1-5). The genes encoding human SSTR1-5 are located in chromosome 14q13, 17q24, 22q13.1, 20p11.2 and 16p13.3. SSTR expression pattern and complex signaling make somatostatin be such an extraordinary neurotransmitter and hormone. The potent inhibitory action of SSTR on cellular processes such as secretion, proliferation, and apoptosis is the reason for somatostatin to be the target for therapy development. Radiopharmaceuticals used for therapy consist of three parts: somatostatin analog, chelator, and radionuclide (alpha or beta-emitting). Combinations of different peptides, chelators, and radionuclides have been tested in vitro and/or in vivo for their use in peptide receptor radionuclide therapy (PRRT). These compounds are able to irradiate tumors and their metastases via the internalization through a specific receptor subtype which is generally overexpressed on the cell membrane.
References
2. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(4068):77-9.
3. Burgus R, Ling N, Butcher M, Guillemin R. Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proceedings of the National Academy of Sciences. 1973;70(3):684-8.
4. Müldner M, Dydejczyk A. Somatostatin: The History of Discovery. edisi. Dydejczyk A, Signore A, De Jong M, Dierckx R, Buscombie J, Van de Wiele C, editor. New Jersey: John Wiley & Sons Inc; 2015.
5. Hellman B, Lernmark Å. Evidence for an inhibitor of insulin release in the pancreatic islets. Diabetologia. 1969;5(1):22-4.
6. Koerker DJ, Ruch W, Chideckel E, Palmer J, Goodner CJ, Ensinck J, et al. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science. 1974;184(4135):482-4.
7. Polak J, Grimelius L, Pearse A, Bloom S, Arimura A. Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells. The Lancet. 1975;305(7918):1220-2.
8. Spiess J, Rivier JE, Rodkey JA, Bennett CD, Vale W. Isolation and characterization of somatostatin from pigeon pancreas. Proceedings of the National Academy of Sciences. 1979;76(6):2974-8.
9. Werner H, Fridkin M, Aviv D, Koch Y. Immunoreactive and bioactive somatostatin-like material is present in tobacco (Nicotiana tabacum). Peptides. 1985;6(5):797-802.
10. Böhlen P, Brazeau P, Benoit R, Ling N, Esch F, Guillemin R. Isolation and amino acid composition of two somatostatin-like peptides from ovine hypothalamus: somatostatin-28 and somatostatin-25. Biochemical and biophysical research communications. 1980;96(2):725-34.
11. Larsson L-I, Holst J, Kühl C, Lundqvist G, Hirsch M, Ingemansson S, et al. Pancreatic somatostatinoma: clinical features and physiological implications. The Lancet. 1977;309(8013):666-8.
12. Yen SS, Siler TM, DE Vane GW. Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. New England Journal of Medicine. 1974;290(17):935-8.
13. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life sciences. 1982;31(11):1133-40.
14. Reubi JC, Rivier J, Perrin M, Brown M, Vale W. Specific high affinity binding sites for somatostatin-28 on pancreatic 6-cells: Differences with brain somatostatin receptors. Endocrinology. 1982;110(3):1049-51.
15. Reubi JC, Maurer R, Von Werder K, Torhorst J, Klijn J, Lamberts S. Somatostatin receptors in human endocrine tumors. Cancer Research. 1987;47(2):551-8.
16. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi J-C, et al. Purification, Biologic Activity, and In Vivo. J Nucl Med. 1990;31:1501-9.
17. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177 Lu-DOTA 0, Tyr 3] octreotate: comparison with [111 In-DTPA 0] octreotide in patients. European journal of nuclear medicine. 2001;28(9):1319-25.
18. Theodoropoulou M. Physiology of Endogenous Somatostatin Family: Somatostatin Receptor Subtypes, Secretion, Function and Regulation, and Organ Specific Distribution. edisi. Dydejczyk A, Signore A, De Jong M, Dierckx R, Buscombie J, Van de Wiele C, editor. New Jersey: John Wiley & Sons Inc; 2015.
19. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. The Journal of clinical investigation. 1997;99(4):789-98.
20. Day R, Dong W, Panetta R, Kraicer J, Greenwood M, Patel Y. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology. 1995;136(11):5232-5.
21. Volantem M, Cassentim A, Rapa I, Righi L, Papotti M. Somatostatin Receptors in Malignancies and Other Pathologies. edisi. Dydejczyk A, Signore A, De Jong M, Dierckx R, Buscombie J, Van de Wiele C, editor. New Jersey: John Wiley & Sons Inc; 2015.
22. Hernaez-Ortega MC, Soto-Pedre E, Piniés JA. Lanreotide Autogel® for persistent diabetic macular edema. Diabetes research and clinical practice. 2008;80(3):e8-e10.
23. Patel Y, Greenwood M, Warszynska A, Panetta R, Srikant C. All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochemical and biophysical research communications. 1994;198(2):605-12.
24. VLiet E, Kam B, Teunissen J, De Jong M, Krenning E, Kwekkeboom D. Somatostatin Receptors in Malignancies and Other Pathologies. edisi. Dydejczyk A, Signore A, De Jong M, Dierckx R, Buscombie J, Van de Wiele C, editor. New Jersey: John Wiley & Sons Inc; 2015.
25. Reubi JC, Schär J-C, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. European journal of nuclear medicine. 2000;27(3):273-82.
26. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination Radionuclide Therapy Using^ sup 177^ Luand^ sup 90^ Y-Labeled Somatostatin Analogs. The Journal of Nuclear Medicine. 2005;46:13S.
27. Bodei L, Paganelli G. Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application. edisi. Dydejczyk A, Signore A, De Jong M, Dierckx R, Buscombie J, Van de Wiele C, editor. New Jersey: John Wiley & Sons Inc; 2015.